Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment

Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment

Mitotane is used as a post-operative adjuvant treatment for patients with adrenocortical carcinoma. Monitoring of plasma mitotane concentrations is recommended, but we do not know what impact target concentrations have on patient outcome. To answer this question, we retrospectively analyzed patient...

Full description

Bibliographic Details
Main Authors: Soraya Puglisi, Anna Calabrese, Vittoria Basile, Filippo Ceccato, Carla Scaroni, Chiara Simeoli, Massimo Torlontano, Salvatore Cannavò, Giorgio Arnaldi, Antonio Stigliano, Pasqualino Malandrino, Laura Saba, Barbara Altieri, Silvia Della Casa, Paola Perotti, Paola Berchialla, Giuseppina De Filpo, Letizia Canu, Paola Loli, Giuseppe Reimondo, Massimo Terzolo
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Journal of Clinical Medicine
Subjects:
adrenocortical carcinoma
mitotane
prognosis
recurrence
survival
Online Access:https://www.mdpi.com/2077-0383/8/11/1850

Internet

https://www.mdpi.com/2077-0383/8/11/1850

Similar Items